ST. PAUL, Minn., Sept. 21, 2016 /PRNewswire/ -- EnteroMedics
Inc. (NASDAQ: ETRM), the developer of medical devices using
neuroblocking technology to treat obesity, metabolic diseases and
other gastrointestinal disorders, today announced that the Company
will present at the Ladenburg Thalmann Healthcare Conference at the
Sofitel New York Hotel on Tuesday, September
27, 2016 at 4:00 p.m. ET.
About EnteroMedics Inc.
EnteroMedics is a medical device company focused on the
development and commercialization of its neuroscience based
technology to treat obesity and metabolic diseases.
vBloc® Neurometabolic Therapy, delivered by a
pacemaker-like device called the vBloc® System, is
designed to intermittently block the vagus nerves using
high-frequency, low-energy, electrical impulses. EnteroMedics'
vBloc® System has received U.S. Food and Drug Administration
approval and CE Mark.
Information about the vBloc® System and
vBloc® Neurometabolic Therapy
You should not have an implanted vBloc® System if you have
cirrhosis of the liver, high blood pressure in the veins of the
liver, enlarged veins in your esophagus or a significant hiatal
hernia of the stomach; if you need magnetic resonance imaging
(MRI); if you have a permanently implanted, electrical medical
device; or if you need a diathermy procedure using heat. The most
common related adverse events that were experienced during clinical
study of the vBloc System included pain, heartburn, nausea,
difficulty swallowing, belching, wound redness or irritation, and
constipation.
Talk with your doctor about the full risks and benefits of vBloc
Therapy and vBloc System. For additional prescribing information,
please visit www.enteromedics.com.
If you are interested in learning more about vBloc
Neurometabolic Therapy, please visit www.vbloc.com or call
1-800-MY-VBLOC.
Forward-Looking Safe Harbor Statement:
This press release contains forward-looking statements about
EnteroMedics Inc. Our actual results could differ materially from
those discussed due to known and unknown risks, uncertainties and
other factors including our limited history of operations; our
losses since inception and for the foreseeable future; our limited
commercial sales experience with our vBloc® System for the
treatment of obesity in the United
States or in any foreign market other than Australia and the European Community; our
ability to regain and then maintain compliance with the Nasdaq
continued listing requirements; our ability to commercialize our
vBloc® System; our dependence on third parties to initiate and
perform our clinical trials; the need to obtain regulatory approval
for any modifications to our vBloc® System; physician adoption of
our vBloc® System and vBloc® Neurometabolic Therapy; our
ability to obtain third party coding, coverage or payment levels;
ongoing regulatory compliance; our dependence on third party
manufacturers and suppliers; the successful development of our
sales and marketing capabilities; our ability to raise additional
capital when needed; international commercialization and operation;
our ability to attract and retain management and other personnel
and to manage our growth effectively; potential product liability
claims; potential healthcare fraud and abuse claims; healthcare
legislative reform; and our ability to obtain and maintain
intellectual property protection for our technology and products.
These and additional risks and uncertainties are described more
fully in the Company's filings with the Securities and Exchange
Commission, particularly those factors identified as "risk factors"
in the annual report on Form 10-K filed March 28, 2016. We are providing this information
as of the date of this press release and do not undertake any
obligation to update any forward-looking statements contained in
this document as a result of new information, future events or
otherwise.
Logo - http://photos.prnewswire.com/prnh/20160502/362531LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/enteromedics-to-present-at-the-ladenburg-thalmann-healthcare-conference-300331364.html
SOURCE EnteroMedics Inc.